MGI Tech
华大智造
Executive Summary
MGI Tech is a Shenzhen-based genomic sequencing technology company designated under the BIOSECURE Act, making it off-limits for US pharma partnerships. The company specializes in DNA sequencing instruments and reagents, competing directly with Illumina in the genomics space. While they have strong technology capabilities in sequencing platforms, their BIOSECURE designation creates insurmountable regulatory barriers for US deals. Any engagement would require complete divestiture from Chinese operations, making partnerships commercially unviable.
Structure: MGI Tech trades on Shanghai's STAR Market (688114.SS) as a Chinese public company. Without detailed subsidiary information available, typical structure would likely involve multiple operating entities across China for manufacturing and R&D operations. Due diligence would need to map complete corporate structure to assess BIOSECURE exposure across all affiliates.
Latest Financials
Revenue: 1869062681.62, Net Profit: -463354782.9. Source: East Money (688114)
Period: 2024-09-30 | Source: eastmoney
Ownership & Shareholder Structure
BGI Genomics → MGI Tech
BGI Group controls both BGI Genomics and MGI Tech through the parent entity BGI Group (深圳华大基因集团). The exact shareholding structure involves multiple layers of Chinese holding companies.
Corporate Events
华大智造：上海市锦天城（深圳）律师事务所关于深圳华大智造科技股份有限公司二〇二六年第二次临时股东会的法律意见书
CNINFO announcement for MGI Tech (688114.SS)
华大智造：2026年第二次临时股东会决议公告
CNINFO announcement for MGI Tech (688114.SS)
华大智造：2026年第二次临时股东会会议资料
CNINFO announcement for MGI Tech (688114.SS)
华大智造：上海市锦天城（深圳）律师事务所关于深圳华大智造科技股份有限公司二〇二六年第一次临时股东会的法律意见书
CNINFO announcement for MGI Tech (688114.SS)
华大智造：2026年第一次临时股东会决议公告
CNINFO announcement for MGI Tech (688114.SS)
MGI Tech Financial Report
Revenue: 1869062681.62, Net Profit: -463354782.9. Source: East Money (688114)
BIOSECURE Risk
Company is explicitly designated under the BIOSECURE Act as a covered entity, creating absolute prohibition on US government contracts and strong disincentives for private sector engagement
Key Exposures:
- •Direct BIOSECURE Act designation
- •Chinese genomics/biotechnology sector focus
- •Potential data security concerns with genomic sequencing platforms
- •Supply chain dependencies in restricted technology areas
Mitigation: No public mitigation efforts identified - designation creates permanent regulatory barrier for US partnerships
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity data available - BIOSECURE status likely limiting international partnerships
Approach: Do not engage - BIOSECURE designation creates insurmountable regulatory barriers for US pharma partnerships
Red Flags
- ⚠BIOSECURE Act designated entity
- ⚠Limited public disclosure on corporate structure
- ⚠No identified key personnel for BD engagement
- ⚠Regulatory restrictions on technology transfer
- ⚠Potential IP and data security concerns in genomics space
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: SEC EDGAR, DoD 1260H List, Congressional Research Service
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.